Recipharm AB and Astimex Pharma AB have announced the formation of a collaboration agreement for the development and manufacture of a pharmaceutical product.
The formulation development work will take place at the Recipharm Pharmaceutical Development site located in Solna close to Stockholm.
Astimex Pharma also has the opportunity to choose Recipharm as the future manufacturer for the product.
Additionally, Astimex is in discussions with Recipharm for engagement to carry out other manufacturing and development contractual projects.
Maria Lundberg, General Manager, Recipharm Pharmaceutical Development commented: “I am convinced that this is the start of a long-term collaboration that will prove beneficial for both companies and we are pleased that Astimex Pharma have chosen to utilize the expertise and flexible development capabilities that our staff and facilities are able to provide.”
Åsa Lintzen, General Manager, Astimex Pharma AB, said: “We are delighted to be working closely with Recipharm on this specific manufacturing and development project. Indeed, it is Recipharm’s recognized partnering approach, combined with its advanced and adaptable capabilities, including its offering at the Solna facility that attracted us in the first place.”
She added: “Moreover, we were looking for a CDMO that we could build a long term relationship with and consequently we are already exploring the scope for working with Recipharm on other projects.”